Stockreport

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy [Yahoo! Finance]

Lexeo Therapeutics, Inc.  (LXEO) 
PDF LX2020 transduction, transcription, and increased protein expression observed across participants with dose-dependent response; mean increase in PKP2 protein of 93% in [Read more]